Prana (PRAN) to Provide Update on PBT2 Efficacy data

July 10, 2009 11:23 AM EDT

Prana Biotechnology (NASDAQ: PRAN) announced that Dr. Craig Ritchie of Imperial College, London will present an update on the clinical efficacy of Prana's PBT2 drug for the treatment of Alzheimer's Disease at the 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. Dr. Ritchie will be presenting a paper on "PBT2 for Alzheimer's Disease: An Update on Clinical Development" as part of the Featured Research Symposium, "New Horizons: From Discovery to Successful Clinical Trials" on Sunday, July 12th at 11:10 am.

Key findings from our Phase IIa clinical trial, first published in Lancet Neurology in July 2008, as well as additional analysis of the efficacy findings which further support the potential of PBT2 to help Alzheimer's Disease sufferers, will be presented.

The Lancet Neurology paper documented that patients on Prana's PBT2 showed significant improvement in two measures of Executive Function after only 12 weeks of treatment. Dr. Ritchie will present new results showing that there was a statistically significant improvement in the overall Executive Function z-score component of the NTB (Neuropsychological Test Battery) in patients receiving 250mg PBT2 compared with placebo.

Dr. Ritchie will report on the results of a post-hoc analysis of the Phase IIa trial data. An analysis of the responses of individual patients in the trial, showed 41% of those receiving PBT2 demonstrated substantial cognitive improvement compared to only 4% of those on placebo.

Related Categories

FDA
Momentum Movers

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?